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A B S T R A C T
Purpose
To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during
survivorship, information on the impact of chemotherapy is needed. Therefore, we analyzed
gonadal functions in survivors of HL.
Patients and Methods
Women younger than age 40 and men younger than 50 years at diagnosis in ongoing remission
at least 1 year after therapy within the German Hodgkin Study Group HD13 to HD15 trials for early-
and advanced-stage HL were included. Hormone parameters, menstrual cycle, symptoms of
hypogonadism, and offspring were evaluated.
Results
A total of 1,323 (55%) of 2,412 contacted female and male survivors were evaluable for the current
analysis (mean follow-up, 46 and 48 months, respectively). Follicle-stimulating hormone, anti-
Mu¨llerian hormone, and inhibin B levels correlated significantly with therapy intensity (P  .001).
Low birth rates were observed in survivors after advanced-stage treatment within the observation
time (women, 6.5%; men, 3.3%). Regular menstrual cycle was reported by more than 90% of
female survivors of early-stage HL (recovery time mostly  12 months). After six to eight cycles
of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and predni-
sone, menstrual activity was strongly related to age ( v  30 years: 82% v 45%, respectively;
P .001; prolonged recovery time). Thirty-four percent of women age 30 years suffered severe
menopausal symptoms (three- to four-fold more frequently than expected). In contrast, male
survivors had mean levels of testosterone within the normal range and reported no increased
symptoms of hypogonadism.
Conclusion
The present analysis in a large group of survivors of HL provides well-grounded information on
gonadal toxicity of currently used treatment regimens and allows risk-adapted fertility preservation
and comprehensive support during therapy and follow-up.
J Clin Oncol 31:231-239. © 2012 by American Society of Clinical Oncology
INTRODUCTION
High overall survival rates (approximately 90%) in
early- and advanced-stage Hodgkin lymphoma
(HL) have been achieved.1-3 Thus, current clinical
research focuses on the short- and long-term se-
quelae in the growing number of young survivors of
HL. Among these sequelae, infertility and hypogo-
nadismareofparticular importance forpatients and
survivors and demand specializedmedical care.4-8
Health care professionals need comprehensive
information on treatment-related gonadal toxicity.
At diagnosis, physicians should inform the patient
thoroughly and consider protectivemethods to pre-
serve fertility in time. During the follow-up period,
survivors need professional advice when they desire
to have children. Furthermore, it is essential to detect
andmaybe to treat symptoms of hypogonadism. Un-
fortunately, theseissuesarestillnotroutinelyaddressed
bymost physicians.5,9
It is known that the rate of treatment-induced
infertility increaseswithmoreaggressivechemother-
apy.10-14 However, there still are many open ques-
tions about the probability of amenorrhea, reduced
ovarian reserve, and infertility after distinct chemo-
therapies and the impactof ageat treatmentonset, as
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well as about the chance of recovery and the risk of suffering from
symptoms of hypogonadism. Thus, more detailed information is
needed forbothpatients andphysicians.Therefore, themainobjective
of the present analysis is to provide data on the impact of currently
used chemotherapy in HL on gonadal function.
PATIENTS AND METHODS
HD13 to HD15 Trials: Patients and Study Design
Patients (age 18 to 75 years) with biopsy-provenHLwere included in
trials for early favorable (HD13, two cycles of doxorubicin, vinblastine, and
dacarbazine with bleomycin [ABVD] or without bleomycin), early unfa-
vorable (HD14, arm A: four cycles of ABVD or arm B: two cycles of
escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincris-
tine, procarbazine, and prednisone [BEACOPP] followed by two cycles of
ABVD [22]), or advanced-stage HL (HD15, six to eight cycles of esca-
lated BEACOPP or eight cycles of BEACOPP-14).1-3 The studies were
carried out in accordance with the Declaration of Helsinki and the Inter-
national Conference onHarmonisation Good Clinical Practice guidelines.
Assessment of Gonadal Function and Fertility
All survivors (age at randomassignment:women, 18 to39years;men, 18
to 49 years) in ongoing remission at least 1 year after therapy andwithout any
other treatment than the HD13 to HD15 trial medication were addressed. In
women, results were stratified with respect to age (cutoff, 30 years).12,15 In
men, we interpreted inhibin B in the context of follicle-stimulating hormone
(FSH) levels toachieve thehighestpositivepredictivevaluewithacutoff for the
inhibin B/FSH ratio corresponding to proven fertile men and cutoff levels for
FSH and inhibin B corresponding to oligospermia.16,17
Questionnaires
Symptoms of hypogonadism were determined using the Menopause
Rating Scale (MRS) and the Aging Males’ Symptoms scale.18-21 Additional
questions referred to the use of hormonal substitution, methods of fertility
preservation before therapy,menstrual status, pregnancies and offspring after
normal and in vitro fertilization, and social aspects.
Hormone Analysis
Survivorswereaskedtotakeabloodsample(samples forwomenweretaken
on day 3 of a newmenstrual cycle or at the end of the pill break). Blood samples
were then centrally processed and stored at80°C until analysis. Tests included
standardized assays for FSH, luteinizing hormone (LH), estradiol, and testoste-
rone (heterogenic, noncompetitive chemiluminescent immunometric assays;
Elecsys-FSH, Elecsys-LH, Elecsys-Estradiol-II, Elecsys-Testosterone-II; Roche
Diagnostics, Mannheim, Germany); anti-Mu¨llerian hormone (AMH; active
AMHGen-II ELISA; BeckmanCoulter, Prague, CzechRepublic); and inhibin
B (inhibin B Gen-II ELISA-KIT; Beckman Coulter).
Statistics
In female survivors (40yearsoldatfirstdiagnosisofHLand45years
old at time of fertility assessment), results are reported in age groups (18 to 29
years and 30 to 45 years). For men, the upper age limit at time of fertility
assessmentwas 57 years.Outcomemeasures of female fertilityweremenstrual
activity, time to resumption of menstrual activity, hormone values, MRS,
offspring, and pregnancies after therapy. Hormone levels were natural log-
transformedbefore statistical computations to normalize distributions. Fertil-
ity parameters in HD15 survivors are additionally stratified for the use of
gonadotropin-releasinghormone (GnRH)analogs.Results arepresentedwith
descriptive statistics and 95% CIs. To provide a more detailed analysis of age
effects in female survivors, we computed a logistic regression of amenorrhea
on age, with time since end of chemotherapy as covariate. Additionally, gen-
eralized Kaplan-Meier estimates of time to resumption of menstrual activity
are provided for age groups. For analyses ofmale survivors, FSH and LHwere
log-transformed before any statistical computations; inhibin B, testosterone,
and the inhibinB/FSH ratiowere not transformedbecause these variables and
their residuals showed no major deviations from normality. Correlations
betweenhormone levels andrelevantparameters suchasageor follow-up time
were assessed using linear regressionmodels within treatment groups.
The level of significance was set at P  .05 (two-sided). Continuous
parameters were tested with parametric tests for independent groups (t test,
analysis of variance), categorical datawere testedwithexact andbinomial tests,
and no corrections for multiple testing were applied. All statistical analyses
were computed with SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
A total of 1,323 (55%) of 2,412 contacted survivors participated
(562 women and 761 men; Fig 1). In women and men, mean age at
fertility assessmentwas 32 and 38 years, respectively, andmean obser-
vation time from the end of treatment was 46 and 48months, respec-
tively. Comparing all trials, there were unfavorable conditions for
patients treated in the HD13 trial, with higher age at fertility assess-
ment (women, 36 years; men, 40 years) and a higher proportion of
patients having children before therapy (women, 47%; men, 57%).
There were balanced conditions for patients treated in the HD14 and
HD15 trials (Table 1). Comparison of the participating and nonpar-
ticipating patients qualifying for our analysis showed no relevant dif-
ferences (Appendix Table A1, online only).
Female Survivors
Hormones in female survivors. Differences in favor of early-stage
patients treated with fewer cycles (two to four instead of six to eight
cycles) of less intensive chemotherapy were high and significant for
AMH and FSH in both age groups (P .001). Hormone levels were
All survivors addressed 
   HD13
   HD14
   HD15
   Total
Inclusion criteria: age 18-39 
years (women), 18‐49
years (men), no relapse or 
progress; ≥ 1 year after 
therapy
Not participating 
   survivors 
   HD13
   HD14
   HD15
   Total
(n = 168)
(n = 406)
(n = 515)
(n = 1,089)
 
(n = 316)
(n = 932)
(n = 1,164)
(n = 2,412)
Participating survivors 
   HD13
   HD14
   HD15
   Total
 
(n = 148)
(n = 526)
(n = 649)
(n = 1,323)
Female survivors included 
   HD13
   HD14
   HD15
   Total
 
(n = 56)
(n = 274)
(n = 232)
(n = 562)
Male survivors included 
   HD13
   HD14
   HD15
   Total
 
(n = 92)
(n = 252)
(n = 417)
(n = 761)
Fig 1. CONSORT diagram.
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different with respect to age; mean AMH levels greater than 2 g/L
were only observed in women younger than 30 years after ABVD
therapy (Table 2).AfterHD15 therapy,meanAMHlevelswere 0g/L
in both age groups, and the highest FSH levels were measured (mean
FSH:  30 years, 11.1 U/L;  30 years, 29.7 U/L). Serum levels of
AMH and FSH differed between treatment groups in the HD14 trial.
These differences in favor of ABVDwere high and significant for FSH
in older women (mean FSH in women age 30 to 45 years: arm A, 4.4
U/L; arm B, 11.8 U/L; P  .001) and for AMH in both age groups
(mean AMH in women age 30 years: arm A, 2.3 g/L; arm B, 0.9
g/L; P  .001; mean AMH in women age  30 years: arm A, 0.7
g/L; arm B, 0.0 g/L; P  .001).22 In contrast, no difference was
found between the three BEACOPP arms of theHD15 trial (P .15).
Regular cycle and time to resumption of menstrual activity. In
both age groups, more than 90% of survivors after treatment for
early-stage HL reported a regular cycle after therapy, and time to
resumption of menstrual activity was mostly reached within 1 year
(Fig 2A). After treatment for advanced-stage HL, 82% of women
younger than 30 years had a regular cycle, comparedwith only 45%of
women in the older age group (Table 2). There was no difference
regarding whether or not women had received cotreatment with
GnRH analogs. Time to resumption of menstrual activity took con-
siderably longer than inearly-stagepatients andwas strongly related to
age (Fig 2A). Themean age ofwomenwith sustained amenorrheawas
31.6 years at start of chemotherapy (95% CI, 30.5 to 32.8 years),
whereas the mean age of women with a regular cycle was 27.1 years
Table 1. Patient Characteristics
Characteristic
Female Patients Male Patients
HD13 (n  56)
HD14
(n  274)
HD15
(n  232)
Total
(n  562)
Total
(n  761) HD13 (n  92)
HD14
(n  252)
HD15
(n  417)
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
Age at fertility assessment,
years
Mean 35 32 32 32 38 40 37 38
Standard deviation 7 7 7 7 9 8 9 9
Range 21-44 20-45 20-45 20-45 19-57 21-54 19-54 20-57
Age at HL diagnosis, years
Mean 31 28 27 28 34 36 34 33
Standard deviation 6 7 6 7 9 9 9 9
Range 18-39 18-39 18-39 18-39 18-49 18-49 18-49 18-49
Time from end of chemotherapy,
months
Mean 45 43 50 46 48 50 44 51
Standard deviation 23 20 20 20 20 24 19 19
Range 12-96 12-83 12-91 12-96 12-103 12-103 12-79 12-94
Clinical stage
I 4/45 9 10/274 4 14/549 2 36/736 5 25/68 37 11/251 4
II 41/45 91 260/274 96 59/230 26 364/549 66 341/736 46 43/68 63 240/251 96 58/417 14
III 105/230 46 105/549 19 225/736 31 225/417 54
IV 66/230 29 66/549 12 134/736 18 134/417 32
“B” symptoms present 7/45 16 56/274 20 145/230 63 208/549 38 362/736 49 8/68 12 81/251 32 273/417 66
Chemotherapy
Two cycles of A(B)VD 56/56 100 56/562 10 92/761 12 92/92 100
Four cycles of ABVD 139/274 51 139/562 25 120/761 16 120/252 48
22 135/274 49 132/562 23 132/761 17 132/252 52
Eight cycles of escalated
BEACOPP 79/232 34 79/562 14 142/761 19 142/417 34
Six cycles of escalated
BEACOPP 75/232 32 75/562 13 146/761 19 146/417 35
Eight cycles of BEACOPP-14 79/232 34 79/562 14 129/761 17 129/417 31
Parenthood before, yes 23/49 47 96/255 38 85/219 39 204/523 39 323/705 46 50/88 57 101/233 43 172/384 45
Oral contraception, yes 15/54 28 86/268 32 46/231 20 147/553 27
GnRH, yes 10/54 19 62/268 23 77/231 33 149/553 27
Oral contraception now, yes 25/54 46 131/268 49 134/231 58 290/553 52
Cryopreservation of sperm (men)
or oocytes or ovarian tissue
(women), yes† 3/52 6 21/257 8 20/214 8 44/523 9 274/724 38 26/88 30 101/239 42 147/397 37
Sex partner now, yes 52/55 95 240/265 91 174/219 80 466/539 87 593/713 83 76/86 88 197/236 84 320/391 82
Abbreviations: A(B)VD, doxorubicin, (bleomycin), vinblastine, and dacarbazine; ART, assisted reproduction; BEACOPP, bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone; GnRH, gonadotropin-releasing hormone; HL, Hodgkin lymphoma; 22, two cycles of BEACOPP
followed by two cycles of ABVD.
Total No. represents number of patients with valid data, and percentages represent percentages of patients with valid data.
†Cryopreservation of fertilized oocytes, n  6; cryopreservation of unfertilized oocytes, n  11; cryopreservation of oocytes not further specified, n  4;
cryopreservation of ovarian tissue, n  16; cryopreservation of both oocytes and ovarian tissue, n  1; and cryopreservation not further specified, n  6.
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Table 2. Fertility Parameters of Female Survivors After Six Randomly Assigned Treatments in Two Age Groups (18 to 29 years and 30 to 45 years)
Parameter
HD13: Two
Cycles of
A(B)VD
HD14
HD15
HD15†Four Cycles of
ABVD 22
Eight Cycles
of Escalated
BEACOPP
Six Cycles of
Escalated
BEACOPP
Eight Cycles
of BEACOPP-
14 GnRH No GnRH
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
Age 30-45 years 39 88 72 38 46 50 34 100
Hormones
AMH, g/L‡
Mean 0.7 0.7 0.0 0.0 0.0 0.0 0.0 0.0
95% CI 0.3 to 1.6 0.5 to 1.1 0.0 to 0.1 0.0 to 0.0 0.0 to 0.0 0.0 to 0.1 0.0 to 0.1 0.0 to 0.0
FSH, U/L‡
Mean 7.5 4.4 11.8 41.2 23.6 29.3 25.9 31.5
95% CI 5.9 to 9.6 3.4 to 5.8 8.2 to 16.9 28.2 to 60.2 14.6 to 38.2 20.3 to 42.2 15.4 to 43.7 24.1 to 41.1
FSH, U/L‡ (sensitivity§)
Mean 6.9 5.1 10.7 41.4 28.8 34.5 23.8 38.0
95% CI 5.1 to 9.3 3.8 to 6.8 7.1 to 16.3 25.7 to 66.7 16.0 to 52.1 20.3 to 58.8 11.3 to 50.2 27.3 to 53.0
Menopausal symptoms
MRS total score
Mean 9.0 9.0 9.6 12.2 11.5 12.6 10.4 12.7
95% CI 6.1 to 12.0 7.3 to 10.8 7.6 to 11.6 9.0 to 15.4 8.3 to 4.6 10.0 to 15.2 7.1 to 13.8 10.7 to 14.6
MRS severity
Severe (8%) 7/29 25 14/66 21 13/54 24 13/32 41 11/39 29 13/39 33 8/28 30 29/82 35
Moderate (20%) 5/29 18 12/66 18 10/54 19 6/32 19 11/39 29 15/39 38 5/28 19 27/82 33
Mild (25%) 6/29 21 20/66 30 15/54 28 4/32 13 7/39 18 3/39 8 7/28 26 7/82 9
No/few (48%) 10/29 36 20/66 30 16/54 30 9/32 28 9/39 24 8/39 21 7/28 26 19/82 23
Regular cycle after therapy 36/37 97 77/82 94 65/72 90 13/37 35 24/44 55 22/50 44 16/34 47 43/97 44
Regular cycle after therapy
(sensitivity§) 25/26 96 57/61 93 47/53 89 9/26 35 16/31 52 11/27 41 10/19 53 26/65 40
Regular cycle presently 35/37 95 69/82 84 54/72 75 14/37 38 18/45 40 24/50 48 15/33 45 41/99 41
Regular cycle presently
(sensitivity§) 24/26 92 51/61 84 40/53 75 8/27 30 8/31 26 9/27 33 7/19 37 18/66 27
Pregnancy 6/35 17 14/82 17 20/71 28 4/36 11 5/44 11 4/49 8 3/32 9 10/97 10
Birth 3/31 10 9/76 12 16/62 26 4/36 11 2/42 5 2/46 4 2/31 6 6/93 6
Age 18 to 29 years 17 51 63 41 28 29 43 53
Hormones
AMH, g/L‡
Mean 2.2 2.3 0.9 0.0 0.1 0.0 0.0 0.1
95% CI 1.4 to 3.6 1.5 to 3.5 0.7 to 1.2 0.0 to 0.1 0.1 to 0.2 0.0 to 0.1 0.0 to 0.1 0.0 to 0.1
FSH, U/L‡
Mean 2.4 3.1 4.4 9.8 10.6 13.5 13.6 9.4
95% CI 1.2 to 4.7 2.2 to 4.5 3.2 to 6.1 6.1 to 16.0 6.3 to 18.0 8.3 to 22.1 8.7 to 21.3 6.4 to 13.7
FSH, U/L‡ (sensitivity§)
Mean 2.3 3.9 3.2 12.1 9.9 13.6 13.1 10.8
95% CI 0.8 to 6.7 2.3 to 6.7 1.7 to 5.8 5.8 to 24.9 4.7 to 20.6 6.8 to 26.9 6.2 to 27.8 6.9 to 17.0
Menopausal symptoms
MRS total score
Mean 6.2 7.1 6.3 9.6 8.3 8.9 9.2 8.9
95% CI 3.3 to 9.1 5.2 to 9.0 4.3 to 8.2 7.0 to 12.2 5.4 to 11.1 4.8 to 13.0 6.8 to 11.6 6.4 to 11.3
MRS severity
Severe (8%) 0/13 0 6/40 15 3/47 6 5/29 17 2/21 10 3/20 15 3/30 10 7/40 18
Moderate (20%) 4/13 31 6/40 15 10/47 21 12/29 41 6/21 29 4/20 20 13/30 43 9/40 23
Mild (25%) 4/13 31 13/40 33 10/47 21 5/29 17 6/21 29 6/20 30 7/30 23 10/40 25
No/few (48%) 5/13 38 15/40 38 24/47 51 7/29 24 7/21 33 7/20 35 7/30 23 14/40 35
Regular cycle after therapy 15/16 94 49/49 100 60/60 100 33/39 85 23/26 88 19/27 70 33/43 77 42/49 86
Regular cycle after therapy
(sensitivity§) 8/9 89 21/21 100 29/29 100 16/20 80 14/16 88 12/15 80 26/30 87 16/21 76
Regular cycle presently 14/16 88 45/49 92 59/62 95 34/40 85 21/26 81 25/29 86 36/43 84 44/52 85
Regular cycle presently
(sensitivity§) 8/9 89 19/21 90 28/30 93 16/20 80 13/17 76 13/15 87 16/21 76 26/30 87
Pregnancy 1/16 6 7/50 14 12/60 20 3/40 8 5/27 19 1/28 4 3/43 7 6/52 12
Birth 1/15 7 6/43 14 6/48 13 2/38 5 3/26 12 1/27 4 2/42 5 4/49 8
Abbreviations: A(B)VD, doxorubicin, (bleomycin), vinblastine, and dacarbazine; AMH, anti-Müllerian hormone; BEACOPP, bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; MRS, Menopause Rating
Scale; 22, two cycles of BEACOPP followed by two cycles of ABVD.
Total No. represents number of patients with valid data, and percentages represent percentages of patients with valid data.
†Survivors of the HD15 study grouped according to (nonrandomized) treatment with GnRH.
‡All computations for AMH and FSH are log-transformed values to normalize distributions; table entries are in original units (after exponentiation).
§Sensitivity analysis in a subgroup of survivors who did not take oral contraceptives/hormone replacement therapy.
Classification of MRS total score with reference scores for 45- to 60-year-old German women in parentheses.
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(95% CI, 26.5 to 27.7 years). In advanced-stage patients, the risk of
amenorrhea 4 years after chemotherapy highly correlated with age at
HLdiagnosis (25years25%risk; 30years50%risk;Fig2B). In the
HD15 trial, only three (9%)of 35womenolder than35years at start of
chemotherapy reported a regular cycle after therapy, and in arms A
andB, after six toeight cyclesof escalatedBEACOPP,onlyone (4%)of
23 survivors reported a regular cycle.
Pregnancies and Offspring
In contrast to women after treatment for early-stage HL, fewer
pregnancies were reported in women after treatment for advanced-
stageHL(HD13HD14,n60, 19%;HD15,n22, 10%;Table2).
After HD15 therapy, 51.9% of female survivors reported a desire to
have children, but only 15% reported parenthood at 4 years. In
advanced-stagepatients,GnRHanalogshadno influenceonpregnan-
cies after therapy in contrast to observed results after treatment for
early unfavorable HL.22
Menopausal symptoms. MRS total score showed no significant
difference between HL trials regarding menopausal symptoms in
women  30 years. An age-related increase of severe menopausal
symptoms was observed in all trials. Severe symptoms were four- to
five-fold more frequent in women  30 years after therapy for
advanced-stage HL compared with a 45- to 60-year-old German ref-
erence cohort (Table 2). MRS correlated significantly with menstrual
activity (P .001), aswell aswith LHandFSH levels (P .001).Only
48.9%ofwomenwith severe symptomswereonhormonemedication
at the time of the survey.
Male Survivors
Hormones in male survivors. Serum levels of inhibin B and FSH
were significantly different between trials in favor of early-stage pa-
tients treated with fewer cycles (two to four instead of six to eight
cycles) of less intensive chemotherapy (P .001). Importantly, in the
HD14 trial, FSH and inhibin B values differed significantly between
treatment arms in favor of ABVD. No difference was found between
the three BEACOPP regimens in HD15 (Table 3).
With few exceptions, inhibin B and FSH levels corresponding to
proven fertility (inhibinB/FSHratio23.5ng/U)wereonly seenafter
ABVD or 22 (HD13, 51.2%; HD14, 50.4%; HD15, 0.5%). The
highest proportions of inhibin B and FSH levels corresponding to
oligospermia (inhibin B  80 ng/L and FSH  10 U/L) were mea-
sured after BEACOPP (HD13, 12.2%; HD14, 20.7%; HD15, 88.8%;
Fig 3A). LH levels increased significantly with disease stage (highest
mean value of 7.3U/L afterHD15 treatment; normal range, 1.7 to 8.6
U/L).Mean testosterone levels were within the normal range of 2.8 to
8.0 ng/L after all treatment regimens (Table 3).
Effect of follow-up time and age on inhibin B and FSH levels. A
significanteffectof follow-uptimeoninhibinBandFSHlevels, indicating
a recovery of spermatogenesis, was found after treatment with the 22
regimen (P  .001). Overall, in the HD14 trial, these hormone levels
differedsignificantly in favorof fourcyclesofABVD(P .001);however,
the subgroup of survivors with a follow-up of 4 years showed similar
hormone levels in both treatment groups (Fig 4). No recovery was
found in survivors of advanced-stageHL. Therewas an effect of age in
all three trials, with favorable hormone levels in younger survivors
(HD13: P .08; HD14: P .001; HD15: P .001; data not shown).
Effect of age on testosterone. In survivors after HD14 and HD15
treatment, a significant age effect was found, with higher testosterone
levels in younger men (HD14: P  .002; HD15: P  .001). In a
multivariate analysis adjusting for the effect of study, age remained an
independent predictor of testosterone value (data not shown).
Utilization of cryopreserved sperm, birth rate, and children after
therapy. ThebirthrateaftertreatmentintheHD15trialwassignificantly
lower comparedwith after treatment for early stages (study comparison:
P  .04). Children after natural fertilization were most frequently re-
ported in survivors after early-stage therapy compared with advanced-
stage therapy (22 v two children, respectively, in HD15; Fig 3B). Two
hundred seventy-fourmale survivors (38%) underwent a cryopreser-
vation of spermbefore therapy (Table 1). The proportionwas highest
(71%) in18- to 29-year-oldmen.Twenty-six of these survivors (10%)
used their cryopreserved sperm for assisted reproduction (21 survi-
vors of advanced-stage HL). Thirty-two percent of male survivors
after HD15 therapy reported desire for children, but only 12% re-
ported parenthood at a median follow-up time of 4 years.
Aging Males’ Symptoms scale. Aging male symptoms were not
different between patients in the trials and reference values (Table 3).
No correlation between symptoms and hormonal levels, especially
testosterone, was found.
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DISCUSSION
With a total of 1,323 survivors of HL treated within the German
Hodgkin StudyGroupHD13 toHD15 trials, to our knowledge, this is
the largest detailed study on gonadal function and fertility after chem-
otherapy reported so far. The following major findings emerge from
this analysis:
First, as expected, hormone levels correlate with the intensity
of chemotherapy. In women, age was also a relevant factor for a
reduced ovarian reserve. Normal mean AMH levels ( 2 g/L)
were observed in women younger than 30 years after two to four
cycles of ABVD early-stage treatment, but AMH levels were com-
promised in survivors  30 years old. After treatment with six to
eight cycles of BEACOPP, mean AMH levels were 0 g/L in both
age groups, and the highest FSH levels were measured in women
older than 30 years.
Inmen, half of the survivors after early-stage treatment had FSH
and inhibin B levels corresponding to proven fertile men, whereas
Table 3. Results of Male Survivors
Parameter
HD13: Two
Cycles of
A(B)VD
(n  92)
HD14
HD15
Total (N  761)
Four Cycles of
ABVD
(n  120) 22 (n  132)
Eight Cycles of
Escalated
BEACOPP
(n  142)
Six Cycles of
Escalated
BEACOPP
(n  146)
Eight Cycles of
BEACOPP-14
(n  129)
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
No./Total
No. %
Hormones
FSH, U/L
Mean 5.6 4.4 7.9 19.2 18.7 19.0 11.0
95% CI 4.8 to 6.6 3.9 to 4.9 6.8 to 9.1 17.6 to 21.0 17.3 to 20.3 17.4 to 20.8 10.3 to 11.7
 12.4 U/L 11/84 13 7/116 6 38/130 29 105/128 82 109/137 80 95/113 84 365/708 52
Inhibin B, ng/L
Mean 126.1 162.5 93.9 15.9 16.9 15.4 67.2
95% CI 111.5 to 140.7 149.1 to 176.0 80.5 to 107.2 11.3 to 20.4 12.9 to 20.9 11.4 to 19.3 61.4 to 73.0
 25 ng/L 6/82 7 4/117 3 28/130 22 100/130 77 104/139 75 80/112 71 322/710 45
Inhibin B/FSH ratio, ng/U
Mean 33.4 49.1 25.8 1.5 1.5 1.4 17.5
95% CI 26.0 to 40.8 41.3 to 57.0 18.7 to 32.9 0.8 to 2.1 1.0 to 2.0 0.9 to 1.9 15.1 to 20.0
LH, U/L
Mean 4.8 4.2 5.1 7.4 7.0 7.5 5.9
95% CI 4.3 to 5.3 3.8 to 4.6 4.6 to 5.6 6.7 to 8.2 6.6 to 7.5 6.9 to 8.1 5.7 to 6.2
 8.6 U/L 9/84 11 7/116 6 17/130 13 49/129 38 38/136 28 41/113 36 161/708 23
Testosterone, ng/L
Mean 4.2 4.8 4.7 3.9 4.1 4.3 4.3
95% CI 3.9 to 4.6 4.5 to 5.2 4.4 to 5.0 3.6 to 4.2 3.8 to 4.4 4.0 to 4.6 4.2 to 4.5
 2.8 ng/L 17/84 20 17/116 15 18/130 14 36/129 28 29/137 21 17/113 15 134/709 19
Aging Males’ Symptoms
scale
Total score
Mean 30.8 29.0 30.4 32.6 29.6 30.8 30.6
95% CI 28.2 to 33.3 26.8 to 31.3 28.3 to 32.6 30.4 to 34.8 27.8 to 31.5 28.6 to 33.0 29.7 to 31.4
Impairment†
No (45%) 42/90 47 62/111 56 57/125 46 57/130 44 67/140 48 50/116 43 335/712 47
Little (37%) 19/90 21 25/111 23 42/125 34 32/130 25 39/140 28 36/116 31 193/712 27
Moderate (11%) 18/90 20 17/111 15 13/125 10 24/130 19 27/140 19 19/116 16 118/712 17
Severe (7%) 11/90 12 7/111 6 13/125 10 17/130 13 7/140 5 11/116 10 66/712 9
Utilization of cryopreserved
sperm for ART, yes 3/26 12 0/48 0 1/53 2 8/47 17 7/54 13 7/46 15 26/274 10
Reproduction after therapy
Birth after natural
fertilization 7/76 9 11/104 11 4/112 4 0/117 0 2/131 2 0/112 0 24/652 4
Natural fertilization, but no
birth (yet) 2/76 3 2/104 2 2/112 2 2/117 2 1/131 1 0/112 0 9/652 1
Birth after ART 0/76 0 0/104 0 0/112 0 4/117 3 3/131 2 3/112 3 10/652 2
ART, but no birth (yet) 1/76 1 0/104 0 0/112 0 4/117 3 3/131 2 4/112 4 12/652 2
Abbreviations: A(B)VD, doxorubicin, (bleomycin), vinblastine, and dacarbazine; ART, assisted reproduction; BEACOPP, bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and prednisone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; 22, two cycles of BEACOPP followed by
two cycles of ABVD.
Total No. represents number of patients with valid data, and percentages represent percentages of patients with valid data.
†Classification of Aging Males’ Symptoms total score, with reference scores for German men  40 years in parentheses.
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88.8% of survivors after advanced-stage treatment had levels corre-
sponding to oligospermia. An effect of follow-up time on inhibin B
and FSH levels was found in men after 22 treatment, suggesting a
recovery up to 4 years after intermediate aggressive therapies. In con-
trast to the dose-dependent effect on the spermatogenesis as indicated
by FSH and inhibin B, mean testosterone levels were within the nor-
mal range also after eight cycles of escalated BEACOPP.
Second, recoveryof regular cyclewas reportedbymore than90%
of women after early-stage treatment and was mostly completed
within 1 year. In contrast, after treatment for advanced-stage HL, age
at therapy onset was a decisive factor, and time to resumption of
menstrual activity was considerably longer.
Third, compared with survivors after early-stage therapy, lower
birth rates were observed in survivors after advanced-stage therapy
(women: 15% v 6.5%, respectively; men: 7.2% v 3.3%, respectively).
Of 52%ofwomen and32%ofmenwith desire for children, only 15%
and 12% reported parenthoodwithin amedian observation time of 4
years after advanced-stage therapy, respectively. Finally, female survi-
vors older than age 30 years at diagnosis suffered three- to four-fold
more frequently fromseveremenopausal symptoms comparedwith a
45- to 60-year-old German reference cohort.
Thepresentanalysis combines information fromhormonalanal-
yses with clinical data from large controlled trials and data obtained
from standardized self-reported questionnaires. A portion of survi-
vors didnot respond,whichmight cause a bias.However, all informa-
tion from our original trials indicated no major differences between
participants and nonparticipants (Appendix Table A1). Also, compa-
rable participation rates in all trials indicate a high external validity.
We focused this analysis on thefirst years after chemotherapy, because
gonadal toxicity, recovery, and finally parenthood are relevant prob-
lems within a limited time frame, especially for women.
As expected, chemotherapy-induced gonadal toxicity was high-
est after six to eight cycles of escalated BEACOPP(-14) in both female
and male survivors of HL. After this regimen, hormonal levels reflect
reduced ovarian reserve and amenorrhea indicates impaired fertility
in themajorityofwomen, anda relevant impairmentof spermatogen-
esis occurred in themajority ofmen.However, in advanced-stageHL,
aggressive therapy results in the highest overall survival rates reported
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in large prospective trials.1-3 Thus, balancing efficacy and toxicity is a
difficult task for both patients and physicians. The detailed informa-
tion from our analysis might contribute to a well-balanced shared
decision-making process.
In women with cancer, AMH has been investigated as presumably
valuable cycle-independent marker of the ovarian reserve.23-30 In our
analysis,AMHlevelsweresignificantlyworseaftermore intensivealkylat-
ing agent–containing chemotherapy and with older age. This was also
true for FSH values; however, FSH showed a better differentiation be-
tween the group of women with a regular cycle and the group suffering
fromamenorrheaafter therapy.Additionally, inwomenyounger than30
yearsafteradvanced-stageHL,themeanAMHlevelwas0g/L.However,
weobservedpregnancies inwomenwith lowor evenundetectableAMH
levels, as previously reported in women without history of cancer.31,32
These findings underline the need to further analyze the relevance of
AMH assessment in female survivors of cancer. AMH is obviously not
suited topredict fertility in individualpatients.However, lowAMHlevels
might indicate a reduced ovarian reserve and thus an increased risk of
future premature ovarian failure. This risk cannot be estimated fromour
study because of the limited observation time.33
In addition, chemotherapy-induced amenorrheamight indicate
infertility.12After advanced-stage treatment, age30years at diagno-
sis had the strongest impact on the risk of sustained amenorrhea 4
years after therapy. Surprisingly, inwomen younger than age 30 years,
a high proportion (82%) reported a regular cycle despite escalated
BEACOPP therapy. Nonetheless, overall, women face a relevant risk
of infertility after BEACOPP chemotherapy. The protective effects of
GnRH analogs observed after intermediate aggressive therapies (four
cycles of ABVD or 22),22 however, could not be documented after
BEACOPP therapy for advanced-stage HL in this analysis. Finally,
in the cohort of women  30 years old at diagnosis, we found a
surprisingly high proportion of women with severe menopausal
symptoms.18 Again, age itself had a stronger negative impact on
menopausal symptoms than treatment intensity. Interestingly,
only 48.9% of women with severe symptoms were on hormone
medication at the time of the survey. Because menopausal symp-
toms often substantially affect women’s quality of life andmight be
easy to ameliorate with hormonal replacement therapy, this find-
ing definitively needs further investigation.
Inmale survivors, we found a high proportion (88.8%) of oligo-
spermia, indicated by FSHand inhibinB levels, after six to eight cycles
ofBEACOPP.Evenonly two cycles of escalatedBEACOPP in the 22
regimen induced a marked decrease in the proportion of patients
having hormone levels corresponding to proven fertile men (25%)
comparedwith four cycles of ABVD (50%). This finding underscores
the lower gonadotoxic potential of theABVDregimen.34-36Only 30%
of male survivors after advanced-stage therapy reported desire for
children at 4 years. This observation timemight be too short to finally
judge on paternity, which was documented in only 12men (two after
natural fertilization and 10 after assisted reproduction). Thus, to
maintain the chance for assisted reproduction, cryopreservation of
sperm or testicular sperm extraction must be offered before starting
aggressive therapy.37 Interestingly, levels of testosterone were also
within the normal range after escalated BEACOPP therapy, support-
ing the hypothesis that Leydig cells are more resistant to cytotoxic
chemotherapy.11,34,38,39Also,meanagingmale symptomswerewithin
the normal range in our analysis.
To summarize, survivors after BEACOPP treatment for
advanced-stage disease have the highest risk for symptomatic go-
nadal dysfunction. However, data directly comparing six to eight
cycles ABVD to six to eight cycles of escalated BEACOPP in pa-
tients with HL should be generated to exactly quantify risk of
treatment options in the context of gonadal toxicity.Until then, the
information derived from our analysis may improve both the
shared decision-making process regarding individual treatment
decisions and the guidance during survivorship.
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